Novonesis delivers 8% organic sales growth with an adjusted EBITDA margin of 36.1% in 2024. For 2025, Novonesis presents an outlook of 5-8% organic sales growth with an adjusted EBITDA margin of 37-38%.
COPENHAGEN, Denmark – February 26, 2025. In the 2024 financial year, Novonesis delivers 8% organic sales growth with an adjusted EBITDA margin at 36.1%. The sales growth is driven by both Food & Health Biosolutions and Planetary Health Biosolutions. Volumes have increased by ~6% with pricing contributing ~2% in 2024.
“2024 has been a truly remarkable year. While bringing together two extraordinary companies creating Novonesis, we’ve delivered strong performance across the business. I’m very pleased with our results featuring an 8% organic sales growth and a 36.1% adjusted EBITDA margin. These numbers show the strength of our diversified portfolio and our ability to seize opportunities across industries and markets, even in times of global uncertainty. Looking ahead to 2025, we’re perfectly positioned to accelerate our growth and expand margins even further,” says Ester Baiget, President & CEO, and continues:
“One year ago, we created the world’s leading biosolutions partner Novonesis. We’re now operating as one unified company, powered by 10,000 passionate colleagues going to work every day to better our world with biology. Together, we’re uniquely positioned to address our customers’ – and some of the world’s – most pressing challenges through the power of biosolutions.”
Novonesis launched 45 new innovations during the year. Around 30% of Novonesis’ sales in 2024 came from products introduced in the past five years.
Sustainability
To document Novonesis’ positive impact on the world, the company assesses how its biosolutions contribute positively to the UN Sustainable Development Goals. In 2024, 83% of Novonesis’ sales were documented and aligned with six UN Sustainable Development Goals. Furthermore, Novonesis has reduced its Scope 1 and
